Motus GI Holdings, Inc.

$ Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223040502 Filed on November 13, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.958M	$5.720M	$13.29M
YoY Change	-64.69%	-56.97%	-43.79%
Cash & Equivalents	$5.000M	$5.700M	$13.29M
Short-Term Investments
Other Short-Term Assets	$227.0K	$510.0K	$1.018M
YoY Change	-70.93%	-49.9%	92.08%
Inventory	$496.0K	$781.0K	$1.014M
Prepaid Expenses
Receivables	$76.00K	$102.0K	$161.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$5.757M	$6.742M	$15.49M
YoY Change	-62.54%	-56.47%	-37.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$992.0K	$1.101M	$1.395M
YoY Change	-25.13%	-21.08%	-36.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$13.00K	$13.00K	$13.00K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$1.466M	$1.749M	$1.879M
YoY Change	-35.62%	-6.92%	-14.59%
TOTAL ASSETS
Total Short-Term Assets	$5.757M	$6.742M	$15.49M
Total Long-Term Assets	$1.466M	$1.749M	$1.879M
Total Assets	$7.223M	$8.491M	$17.37M
YoY Change	-59.07%	-51.11%	-35.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.842M	$1.470M	$2.696M
YoY Change	-6.45%	-45.47%	15.36%
Accrued Expenses	$169.0K	$220.0K	$248.0K
YoY Change	-31.02%	-11.29%	-17.33%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.033M	$2.781M	$2.453M
YoY Change	-59.2%	13.37%
Total Short-Term Liabilities	$3.270M	$4.529M	$5.467M
YoY Change	-31.86%	-17.16%	106.61%
LONG-TERM LIABILITIES
Long-Term Debt	$1.239M	$2.470M	$5.251M
YoY Change	-73.0%	-52.96%	-37.68%
Other Long-Term Liabilities	$27.00K	$30.00K	$2.009M
YoY Change	-98.06%	-98.51%	-9.75%
Total Long-Term Liabilities	$1.239M	$2.470M	$5.251M
YoY Change	-73.0%	-52.96%	-50.7%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.270M	$4.529M	$5.467M
Total Long-Term Liabilities	$1.239M	$2.470M	$5.251M
Total Liabilities	$4.536M	$10.97M	$16.60M
YoY Change	-69.08%	-33.94%	24.86%
SHAREHOLDERS EQUITY
Retained Earnings	-$154.2M	-$151.4M	-$137.7M
YoY Change	9.05%	9.97%
Common Stock	$0.00	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.687M	-$2.478M	$762.0K
YoY Change
Total Liabilities & Shareholders Equity	$7.223M	$8.491M	$17.37M
YoY Change	-59.07%	-51.11%	-35.87%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Common Stock Value CommonStockValue		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001686850
CY2023Q3	MOTS	Contingent Royalty Obligation ContingentRoyaltyObligation		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2022Q3	MOTS	Costs Of Revenue Impairment Of Inventory CostsOfRevenueImpairmentOfInventory		usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2023Q3	MOTS	Stock Issued During Period Value Issuance Of Common Shares Upon Exercise Of Warrants StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfWarrants		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2022Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
	MOTS	Issuance Of Common Stock For Board Of Directors Compensation IssuanceOfCommonStockForBoardOfDirectorsCompensation		usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse		usd
	MOTS	Fractional Shares Paid In Cash Pursuant To Reverse Stock Split FractionalSharesPaidInCashPursuantToReverseStockSplit		usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt		usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
	MOTS	Common Stock Issued For Prepaid Board Of Directors Compensation CommonStockIssuedForPrepaidBoardOfDirectorsCompensation		usd
	MOTS	Purchase Of Fixed Assets In Prepaid Expenses PurchaseOfFixedAssetsInPrepaidExpenses		usd
	MOTS	Purchase Of Property And Equipment In Accounts Payable And Accrued Expenses PurchaseOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses		usd
	MOTS	Extinguishment Of Contingent Royalty Obligation ExtinguishmentOfContingentRoyaltyObligation		usd
	MOTS	Operating Lease Liabilities Arising From Obtaining Rightofuse Assets OperatingLeaseLiabilitiesArisingFromObtainingRightofuseAssets		usd
	MOTS	Noncash Issuance Costs From Private Placement NoncashIssuanceCostsFromPrivatePlacement		usd
	MOTS	Rightofuse Asset Obtained In Exchange For Lease Obligation RightofuseAssetObtainedInExchangeForLeaseObligation		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38389
	dei	Entity Registrant Name EntityRegistrantName	Motus GI Holdings, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-4042793
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1301 East Broward Boulevard
	dei	Entity Address Address Line2 EntityAddressAddressLine2	3rd Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	Ft. Lauderdale
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33301
	dei	City Area Code CityAreaCode	(954)
	dei	Local Phone Number LocalPhoneNumber	541 8000
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
	dei	Trading Symbol TradingSymbol	MOTS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	578515	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5724000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14042000	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	102000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	59000	usd
CY2023Q3	MOTS	Inventory Current InventoryCurrent	407000	usd
CY2022Q4	MOTS	Inventory Current InventoryCurrent	488000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	509000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	781000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	6742000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	15370000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1101000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1325000	usd
CY2023Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	374000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	511000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	261000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	428000	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13000	usd
CY2023Q3	us-gaap	Assets Assets	8491000	usd
CY2022Q4	us-gaap	Assets Assets	17647000	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1466000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1969000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	220000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	245000	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	62000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	53000	usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	132000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	182000	usd
CY2023Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	2781000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2532000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4529000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4799000	usd
CY2022Q4	MOTS	Contingent Royalty Obligation ContingentRoyaltyObligation	1212000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	34000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	178000	usd
CY2023Q3	MOTS	Convertible Debt Unamortized Discount Noncurrent ConvertibleDebtUnamortizedDiscountNoncurrent	64000	usd
CY2022Q4	MOTS	Convertible Debt Unamortized Discount Noncurrent ConvertibleDebtUnamortizedDiscountNoncurrent	108000	usd
CY2023Q3	MOTS	Convertible Note Noncurrent ConvertibleNoteNoncurrent	3936000	usd
CY2022Q4	MOTS	Convertible Note Noncurrent ConvertibleNoteNoncurrent	3892000	usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	44000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	135000	usd
CY2023Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2470000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4589000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	10969000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	14670000	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	115000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	115000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	530449	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	530449	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	310494	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	310494	shares
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	148935000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	144328000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-151413000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-141351000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-2478000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2977000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8491000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17647000	usd
CY2023Q3	us-gaap	Revenues Revenues	86000	usd
CY2022Q3	us-gaap	Revenues Revenues	278000	usd
	us-gaap	Revenues Revenues	255000	usd
	us-gaap	Revenues Revenues	483000	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	22000	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	83000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	62000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	166000	usd
CY2023Q3	MOTS	Costs Of Revenue Impairment Of Inventory CostsOfRevenueImpairmentOfInventory	26000	usd
	MOTS	Costs Of Revenue Impairment Of Inventory CostsOfRevenueImpairmentOfInventory	221000	usd
	MOTS	Costs Of Revenue Impairment Of Inventory CostsOfRevenueImpairmentOfInventory	159000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	693000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1573000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2906000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4261000	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	188000	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1349000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1367000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3554000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1551000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1978000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5134000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6167000	usd
CY2023Q3	us-gaap	Costs And Expenses CostsAndExpenses	2480000	usd
CY2022Q3	us-gaap	Costs And Expenses CostsAndExpenses	4983000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	9690000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	14307000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2394000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4705000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9435000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13824000	usd
CY2023Q3	MOTS	Gain Loss On Changes In Fair Value Of Contingent Royalty Obligation GainLossOnChangesInFairValueOfContingentRoyaltyObligation	53000	usd
CY2022Q3	MOTS	Gain Loss On Changes In Fair Value Of Contingent Royalty Obligation GainLossOnChangesInFairValueOfContingentRoyaltyObligation	-34000	usd
	MOTS	Gain Loss On Changes In Fair Value Of Contingent Royalty Obligation GainLossOnChangesInFairValueOfContingentRoyaltyObligation	-103000	usd
	MOTS	Gain Loss On Changes In Fair Value Of Contingent Royalty Obligation GainLossOnChangesInFairValueOfContingentRoyaltyObligation	29000	usd
CY2023Q3	MOTS	Finance Income Expense Net FinanceIncomeExpenseNet	222000	usd
CY2022Q3	MOTS	Finance Income Expense Net FinanceIncomeExpenseNet	310000	usd
	MOTS	Finance Income Expense Net FinanceIncomeExpenseNet	707000	usd
	MOTS	Finance Income Expense Net FinanceIncomeExpenseNet	1001000	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-10000	usd
CY2022Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	17000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-23000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-61000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2679000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4964000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10062000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14915000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.28
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.28
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-26.99
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-26.99
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-20.80
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-20.80
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-80.97
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-80.97
CY2023Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	626470	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	626470	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	183897	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	183897	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	483711	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	483711	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	184210	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	184210	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2977000	usd
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	19000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	102000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	222000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4386000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-1085000	usd
CY2023Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	731000	usd
CY2023Q2	MOTS	Stock Issued During Period Value Private Placement Offering Net Of Financing Fees StockIssuedDuringPeriodValuePrivatePlacementOfferingNetOfFinancingFees	3070000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	49000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2997000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-963000	usd
CY2023Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	38000	usd
CY2023Q3	MOTS	Stock Issued During Period Value Issuance Of Common Shares Upon Extinguishment Of Contingent Royalty Obligation StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExtinguishmentOfContingentRoyaltyObligation	1071	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	93000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2679000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-2478000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	9657000	usd
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	111000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3004000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	235000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	521000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4811000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	8606000	usd
CY2022Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	6000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	45000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	461000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-5140000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	3972000	usd
CY2022Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	55000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1324000	usd
CY2022Q3	MOTS	Stock Issued During Period Value Fractional Shares Settled In Cash Pursuant To Reverse Stock Split Value StockIssuedDuringPeriodValueFractionalSharesSettledInCashPursuantToReverseStockSplitValue	-11	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	441000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4964000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	762000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10062000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14915000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	341000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	381000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	184000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	195000	usd
	MOTS	Gain Loss On Change In Estimated Fair Value Of Contingent Royalty Obligation GainLossOnChangeInEstimatedFairValueOfContingentRoyaltyObligation	103000	usd
	MOTS	Gain Loss On Change In Estimated Fair Value Of Contingent Royalty Obligation GainLossOnChangeInEstimatedFairValueOfContingentRoyaltyObligation	-29000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	364000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1423000	usd
	MOTS	Issuance Of Common Stock For Board Of Directors Compensation IssuanceOfCommonStockForBoardOfDirectorsCompensation	177000	usd
	MOTS	Impairment Of Inventory ImpairmentOfInventory	221000	usd
	MOTS	Impairment Of Inventory ImpairmentOfInventory	159000	usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	46000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	176000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	253000	usd
	MOTS	Loss On Lease Termination LossOnLeaseTermination	11000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	43000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	52000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	16000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	843000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-266000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	167000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-503000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	79000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-183000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-255000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	9000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	61000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9338000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13429000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	104000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	215000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-104000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-215000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	121000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4544000	usd
	MOTS	Fractional Shares Paid In Cash Pursuant To Reverse Stock Split FractionalSharesPaidInCashPursuantToReverseStockSplit	11000	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	2010000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	3537000	usd
	MOTS	Equity Financing Fees EquityFinancingFees	-524000	usd
	MOTS	Equity Financing Fees EquityFinancingFees	-158000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1124000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4375000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8318000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9269000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14042000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	22563000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5724000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13294000	usd
	us-gaap	Interest Paid Net InterestPaidNet	690000	usd
	us-gaap	Interest Paid Net InterestPaidNet	779000	usd
	MOTS	Common Stock Issued For Prepaid Board Of Directors Compensation CommonStockIssuedForPrepaidBoardOfDirectorsCompensation	58000	usd
	MOTS	Purchase Of Fixed Assets In Inventory PurchaseOfFixedAssetsInInventory	13000	usd
	MOTS	Purchase Of Fixed Assets In Inventory PurchaseOfFixedAssetsInInventory	163000	usd
	MOTS	Purchase Of Fixed Assets In Prepaid Expenses PurchaseOfFixedAssetsInPrepaidExpenses	4000	usd
	MOTS	Purchase Of Property And Equipment In Accounts Payable And Accrued Expenses PurchaseOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses	12000	usd
	MOTS	Financing Fees Included In Accounts Payable And Accrued Expenses FinancingFeesIncludedInAccountsPayableAndAccruedExpenses	38000	usd
	MOTS	Financing Fees Included In Accounts Payable And Accrued Expenses FinancingFeesIncludedInAccountsPayableAndAccruedExpenses	13000	usd
	MOTS	Extinguishment Of Contingent Royalty Obligation ExtinguishmentOfContingentRoyaltyObligation	1109000	usd
	MOTS	Operating Lease Liabilities Arising From Obtaining Rightofuse Assets OperatingLeaseLiabilitiesArisingFromObtainingRightofuseAssets	3000	usd
	MOTS	Noncash Issuance Costs From Private Placement NoncashIssuanceCostsFromPrivatePlacement	264000	usd
	MOTS	Rightofuse Asset Obtained In Exchange For Lease Obligation RightofuseAssetObtainedInExchangeForLeaseObligation	69000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80A_eus-gaap--NatureOfOperations_zqN7IOyQDgd7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 – <span id="xdx_82A_zZseW7Jhi4il">Description of Business</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motus GI Holdings, Inc. (the “Company”) was incorporated in Delaware, U.S.A. in September 2016. The Company and its subsidiaries, Motus GI Technologies, Ltd. and Motus GI, LLC, are collectively referred to as “Motus GI” or the “Company”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has developed the Pure-Vu System, a medical device that has been cleared by the U.S. Food and Drug Administration (the “FDA”) to help facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and to help facilitate upper gastrointestinal (“GI”) endoscopy procedures. The Pure-Vu System has received a CE Mark in the EU for use in colonoscopy. The Pure-Vu System integrates with standard and slim colonoscopes, as well as gastroscopes, to improve visualization during colonoscopy and upper GI procedures while preserving established procedural workflow and techniques. Through irrigation and evacuation of debris, the Pure-Vu System is designed to provide better-quality exams. The Company received 510(k) clearance in October 2023 from the FDA for the Pure-Vu EVS System for use in the Upper GI tract and Gen 4 Colon and will commence market introduction of this product in the coming months. Both devices leverage the same Workstation and feature key enhancements such as a larger and more powerful suction channel, more efficient irrigation jets, a smaller profile distal tip that offers enhanced flexibility during insertion, enhanced navigation and a much easier bed side set up. The Company does not expect to generate significant revenue from product sales until it further expands its commercialization efforts, which is subject to significant uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Net Income Loss NetIncomeLoss	-10100000	usd
	MOTS	Net Cash Used In Operating Activities NetCashUsedInOperatingActivities	-9300000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5700000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-151400000	usd
CY2023Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	35000	shares
CY2023Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On November 2, 2023, the Company effected a reverse stock split of its issued and outstanding common stock, par value $0.0001 per share, at a ratio of 1-for-15 (the “2023 Reverse Stock Split”)
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84D_eus-gaap--UseOfEstimates_zS3FYHF5rAZ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zxYlfTeQP8gi">Use of estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	375811	shares
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	54510	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	375811	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	54510	shares
	MOTS	Rate Of Royalty Payment RateOfRoyaltyPayment	0.03	pure
CY2022	MOTS	Rate Of Royalty Payment RateOfRoyaltyPayment	0.03	pure
CY2023Q3	MOTS	Cost Of Revenue Impairment Of Inventory CostOfRevenueImpairmentOfInventory	26000	usd
	MOTS	Cost Of Revenue Impairment Of Inventory CostOfRevenueImpairmentOfInventory	221000	usd
CY2022Q3	MOTS	Cost Of Revenue Impairment Of Inventory CostOfRevenueImpairmentOfInventory	0	usd
	MOTS	Cost Of Revenue Impairment Of Inventory CostOfRevenueImpairmentOfInventory	159000	usd
CY2023Q3	MOTS	Operating Lease Cost Net OperatingLeaseCostNet	-36000	usd
CY2022Q3	MOTS	Operating Lease Cost Net OperatingLeaseCostNet	16000	usd
	MOTS	Operating Lease Cost Net OperatingLeaseCostNet	-18000	usd
CY2023Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	554000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	697000	usd
CY2023Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	177000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	155000	usd
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	672000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	548000	usd
CY2023Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	622000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	401000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	781000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	999000	usd
CY2023Q3	MOTS	Inventory Current InventoryCurrent	407000	usd
CY2022Q4	MOTS	Inventory Current InventoryCurrent	488000	usd
CY2023Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	374000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	511000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3335000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3218000	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2234000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1893000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1101000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1325000	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	111000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	341000	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	128000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	381000	usd
CY2022Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	10000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	46000	usd
	MOTS	Operating Lease Cost Net OperatingLeaseCostNet	78000	usd
CY2023Q3	us-gaap	Variable Lease Cost VariableLeaseCost	103000	usd
CY2022Q3	us-gaap	Variable Lease Cost VariableLeaseCost	30000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	167000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	90000	usd
CY2023Q3	us-gaap	Lease Cost LeaseCost	67000	usd
CY2022Q3	us-gaap	Lease Cost LeaseCost	46000	usd
	us-gaap	Lease Cost LeaseCost	149000	usd
	us-gaap	Lease Cost LeaseCost	168000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	261000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	428000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	220000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	245000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	34000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	178000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	254000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	423000	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y4M9D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M14D
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0733	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0736	pure
CY2023Q3	us-gaap	Direct Taxes And Licenses Costs DirectTaxesAndLicensesCosts	67000	usd
CY2022Q3	us-gaap	Direct Taxes And Licenses Costs DirectTaxesAndLicensesCosts	66000	usd
	us-gaap	Direct Taxes And Licenses Costs DirectTaxesAndLicensesCosts	202000	usd
	us-gaap	Direct Taxes And Licenses Costs DirectTaxesAndLicensesCosts	173000	usd
	us-gaap	Interest Expense Other InterestExpenseOther	690000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	184000	usd
	us-gaap	Interest Expense InterestExpense	874000	usd
CY2023Q3	us-gaap	Interest Expense Other InterestExpenseOther	220000	usd
CY2023Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	61000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	281000	usd
CY2023Q3	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	88221	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	8821	shares
	MOTS	Gain Loss On Settlement Equity Additional Paid In Capital GainLossOnSettlementEquityAdditionalPaidInCapital	<p id="xdx_89A_ecustom--GainLossOnSettlementEquityAdditionalPaidInCapital_zBLoTTZh0bA7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zr5gEVwF8Gzk"> Schedule of Extinguishment of Royalty Obligation</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20230101__20230912_zzrSOBRcQnSe" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Extinguishment of Royalty</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Obligation </b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_403_ecustom--ContingentRoyaltyObligation_i01S_pn3n3_maLzgSy_zbze0jKEnCof" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%; text-align: justify">Balance at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,212</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--GainLossOnChangeInEstimatedFairValueOfContingentRoyaltyObligation_iN_pn3n3_di_msNCPBUzwDp_zvpXnmiRSun7" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Change in estimated fair value of royalty obligation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(103</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_ecustom--ContingentRoyaltyObligation_i01E_pn3n3_maLzgSy_zgD7qcvCKkF7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Balance at September 12, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,109</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--ContingentRoyaltyObligation_i01E_pn3n3_maLzgSy_z71M4jCmwFLa" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Contingent royalty obligation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,109</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--CommonStockExchangedForExtinguishmentOfRoyaltyObligation_i01N_pn3n3_di_z60xPuY9YB12" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less fair value of common stock exchanged for extinguishment of royalty obligation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">711</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_pn3n3_zXRMmoiGa397" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Gain on extinguishment – recorded within additional paid-in-capital</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">398</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2022Q4	MOTS	Contingent Royalty Obligation ContingentRoyaltyObligation	1212000	usd
	MOTS	Gain Loss On Change In Estimated Fair Value Of Contingent Royalty Obligation GainLossOnChangeInEstimatedFairValueOfContingentRoyaltyObligation	103000	usd
CY2023Q3	MOTS	Contingent Royalty Obligation ContingentRoyaltyObligation	1109000	usd
CY2023Q3	MOTS	Contingent Royalty Obligation ContingentRoyaltyObligation	1109000	usd
	MOTS	Common Stock Exchanged For Extinguishment Of Royalty Obligation CommonStockExchangedForExtinguishmentOfRoyaltyObligation	-711000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	398000	usd
CY2023Q3	MOTS	License Fees LicenseFees	67000	usd
	MOTS	License Fees LicenseFees	202000	usd
CY2022Q3	MOTS	License Fees LicenseFees	66000	usd
	MOTS	License Fees LicenseFees	173000	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	93000	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	441000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	364000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1423000	usd
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.0001
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26000	usd
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35000	shares
CY2023Q1	us-gaap	Restructuring And Related Cost Description RestructuringAndRelatedCostDescription	the Company commenced a strategic restructuring program aimed at capital preservation. In April 2023, the Company approved the implementation of additional cost cutting measures, including an executive reorganization and other cuts in clinical expenses, in connection with its ongoing efforts to reduce operating expenses. In addition, the non-management members of the Board agreed to defer their Board fees until a future date
CY2023Q3	us-gaap	Restructuring Charges RestructuringCharges	94000	usd
	us-gaap	Restructuring Charges RestructuringCharges	1517000	usd

Files In Submission

Name	View Source	Status
0001493152-23-040502-index-headers.html	Edgar Link	pending
0001493152-23-040502-index.html	Edgar Link	pending
0001493152-23-040502.txt	Edgar Link	pending
0001493152-23-040502-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex31-3.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mots-20230930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
mots-20230930_cal.xml	Edgar Link	unprocessable
mots-20230930_def.xml	Edgar Link	unprocessable
mots-20230930_lab.xml	Edgar Link	unprocessable
mots-20230930_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

Motus GI Holdings, Inc.

2023 Q4 Form 10-Q Financial Statement

#000149315223040502 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission